Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data

Data de publicação:

Autores da FMUP

  • Nuno Miguel De Sousa Lunet

    Autor

Participantes de fora da FMUP

  • Yoo, Sang Gune K.
  • Chung, Grace S.
  • Bahendeka, Silver K.
  • Sibai, Abla M.
  • Damasceno, Albertino
  • Farzadfar, Farshad
  • Rohloff, Peter
  • Houehanou, Corine
  • Norov, Bolormaa
  • Karki, Khem B.
  • Azangou-Khyavy, Mohammadreza
  • Marcus, Maja E.
  • Aryal, Krishna K.
  • Brant, Luisa C. C.
  • Theilmann, Michaela
  • Cifkova, Renata
  • Gurung, Mongal S.
  • Mwangi, Joseph Kibachio
  • Martins, Joao
  • Haghshenas, Rosa
  • Sturua, Lela
  • Vollmer, Sebastian
  • Barnighausen, Till
  • Atun, Rifat
  • Sussman, Jeremy B.
  • Singh, Kavita
  • Moghaddam, Sahar Saeedi
  • Guwatudde, David
  • Geldsetzer, Pascal
  • Manne-Goehler, Jennifer
  • Huffman, Mark D.
  • Davies, Justine I.
  • Flood, David

Unidades de investigação

Abstract

The role of aspirin in the primary prevention of atherosclerotic cardiovascular disease (CVD) is not clear, with recent clinical trials evaluating aspirin for primary prevention demonstrating both modest benefits and risks associated with its use [1]. Aspirin is not routinely recommended for primary prevention of CVD. Understanding patterns of aspirin use can inform strategies to promote guideline-concordant therapy, including de-implementation strategies to reduce unnecessary aspirin use. This study seeks to provide an updated estimate of worldwide aspirin use for primary prevention of CVD. © 2024 The Author(s).

Dados da publicação

ISSN/ISSNe:
2211-8179, 2211-8160

Global Heart  Elsevier Science & Technology

Tipo:
Article
Páginas:
-
Link para outro recurso:
www.scopus.com

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Female; Global Health; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prevalence; Primary Prevention; acetylsalicylic acid; acetylsalicylic acid; antithrombocytic agent; adult; aged; Article; cardiovascular disease; controlled study; cross-sectional study; female; health survey; high income country; human; low income country; major clinical study; male; middle aged; middle income country; prevalence; primary prevention; cardiovascular disease; global health; procedures

Proyectos asociados

Breast cancer heterogeneity - etiology, clinical management, use of health resources and survival

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2022

Longitudinal Assessment of Cognitive Decline in Breast and Prostate Cancer Survivors

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico (Cognitive Decline) . 2022

Healthcare use among cancer patients and their partners in different phases of the cancer pathway

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2021

Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação